Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2023-06-26 Board/Management Inform…
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Board/Management Information 2023
Board/Management Information Classification · 99% confidence The document is titled 'Corporate Release' and announces a significant change in senior management: the Board of Directors initiating CEO succession, with the current CEO retiring and a new CEO appointed, effective by October 1, 2023. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-06-26 English
Director's Dealing 2023
Director's Dealing Classification · 100% confidence The document is titled 'Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties' and details a specific purchase of shares by a Member of the Board of Directors (Jakob Riis) on a specific date (2023-05-12). This content directly corresponds to the reporting of personal share transactions by company directors and executives, which is the definition of Director's Dealing.
2023-05-15 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing Classification · 100% confidence The document is a formal notification of a share transaction by a member of the Board of Directors (Jakob Riis). It explicitly details the nature of the transaction (purchase of shares), the price, volume, and the date of the transaction. This falls under the category of 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2023-05-15 Danish
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a press release announcing the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for the drug Rexulti®. This type of announcement, detailing a significant regulatory event (drug approval) and providing context, executive quotes, and scientific background, is characteristic of a corporate news release. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Earnings Release (ER) which focuses on financial figures. Since it is a specific corporate announcement that doesn't fit the other specialized categories (like Director's Dealing, Capital Change, etc.), and it is a formal communication distributed via a news wire service (Cision), the most appropriate general category for a significant, non-financial, non-meeting related corporate update is Regulatory Filings (RNS), as it reports on a regulatory action (FDA approval). However, given the content is a major corporate milestone announcement, and not just a miscellaneous filing, I must check if there is a better fit. Since the core event is the FDA approval, and it is a formal announcement, RNS serves as the best fit among the provided options for a general regulatory/corporate news announcement that isn't a financial report or meeting material. It is not an RPA because it is the substance of the news, not just an announcement that a report is available.
2023-05-11 English
Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s Disease
Regulatory Filings Classification · 95% confidence The document is a 'Corporate Release' from H. Lundbeck A/S announcing the FDA approval of a supplemental New Drug Application (sNDA) for a specific pharmaceutical product (Rexulti). It details the clinical trial results, the significance of the approval, and provides contact information for investors and media. This type of announcement regarding regulatory approval of a product does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. It falls under the general category of regulatory and corporate announcements, for which 'RNS' (Regulatory Filings) is the designated fallback category.
2023-05-11 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a press release titled "Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention." It details clinical trial outcomes (HOPE trial), efficacy data, safety information, and future development plans for an investigational drug. This content strongly aligns with an Earnings Release (ER) which typically includes key operational and clinical updates, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a specific announcement of clinical trial results, which are crucial operational updates often released outside of the standard quarterly earnings cycle but intended for investors, it fits best as an Earnings Release (ER) or a general Regulatory Filing (RNS). Given the structure and focus on immediate, material operational news (clinical trial success), ER is a strong candidate, but since it is not explicitly stating quarterly/periodical financial results (like revenue/EPS), and is more of a specific corporate event announcement, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for material, non-standard financial news, or ER if we interpret 'Earnings Release' broadly to include material operational news that impacts future earnings potential. Since it is a press release announcing a major R&D milestone, and not a formal financial statement, RNS is safer, but ER often covers major operational news. Given the context of financial reporting databases, major clinical trial results are often categorized alongside ERs or as specific operational updates. Since there is no specific category for 'Clinical Trial Results Announcement', and it is a direct announcement of a material event, I will classify it as an Earnings Release (ER) as it signals future financial performance potential, or RNS. Comparing the definitions, ER is for 'initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, RNS (General regulatory announcements and fallback) is the most accurate fit for a material, non-financial corporate announcement.
2023-04-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.